Testing a New Paradigm of Parkinson’s Disease and Transforming the Clinical Experience

Our guest speaker, Dr. Jonathan Sackner-Bernstein, is a widely sought expert in medical product development, with expertise from first-in-human to post-market stages with deep understanding of regulatory, clinical, operational, analytic, and due-diligence processes. Recently, Dr. Bernstein has identified a novel candidate drug therapy for Parkinson's disease (patent pending), along with working through regulatory steps required to start a clinical trial.
During this webinar, Dr. Bernstein:
- Defines a new paradigm for Parkinson's disease
- Identifies therapeutic implications of this discovery
- Delineates a path to test this new paradigm, and in parallel, the possibility of modifying the disease

[@timhuffy9290]

As a registered nurse with Parkinson disease diagnosis this year, I am very hopeful from your presentation. Even if it only stops progression and does not have reversal of function, that would be huge for someone like me who can still function at my job but if disease progresses, I probably could not.